Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe.
10-valent pneumococcal vaccine
13-valent pneumococcal vaccine
15-valent pneumococcal vaccine
20-valent pneumococcal vaccine
SpIDnet Multicenter Study
Streptococcus pneumoniae
bacteria
invasive pneumococcal disease
pneumococcal infections
respiratory infections
serotype
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
7
1
2022
Statut:
ppublish
Résumé
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. In 2018, serotypes in the 15-valent and 20-valent PCVs represented one third of cases in children <5 years of age and two thirds of cases in persons >65 years of age. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
Identifiants
pubmed: 34932457
doi: 10.3201/eid2801.210734
pmc: PMC8714201
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-138Références
Clin Microbiol Infect. 2020 Jun;26(6):753-759
pubmed: 31756452
Vaccine. 2018 Jan 25;36(4):572-577
pubmed: 29258705
Int J Infect Dis. 2019 Sep;86:122-130
pubmed: 31283992
Lancet Infect Dis. 2019 Dec;19(12):1283-1284
pubmed: 31782390
Vaccine. 2015 Jan 3;33(2):359-66
pubmed: 25448105
PLoS One. 2019 Aug 1;14(8):e0220453
pubmed: 31369597
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Hum Vaccin Immunother. 2019;15(3):530-539
pubmed: 30648919
Epidemiol Mikrobiol Imunol. 2019 Spring;68(2):75-81
pubmed: 31398980
Lancet Respir Med. 2017 Aug;5(8):648-656
pubmed: 28359798
Expert Rev Vaccines. 2018 Jun;17(6):479-493
pubmed: 29241390
Expert Rev Vaccines. 2019 Nov;18(11):1145-1155
pubmed: 31682762
Vaccine. 2017 Aug 16;35(35 Pt B):4587-4593
pubmed: 28716556
Thorax. 2019 May;74(5):473-482
pubmed: 30355641
Vaccine. 2013 Nov 19;31(48):5634-42
pubmed: 23856332
Vaccine. 2019 Jul 26;37(32):4491-4498
pubmed: 31272872
Vaccine. 2019 Sep 30;37(42):6201-6207
pubmed: 31495592
PLoS One. 2017 Jan 6;12(1):e0169368
pubmed: 28061505
Clin Infect Dis. 2020 Nov 5;71(8):e235-e243
pubmed: 31955196
PLoS One. 2015 Jun 30;10(6):e0131117
pubmed: 26125583
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
PLoS One. 2016 Jan 13;11(1):e0146338
pubmed: 26761816
Epidemiol Infect. 2017 Aug;145(11):2390-2399
pubmed: 28712384
Vaccine. 2018 Jan 8;36(3):421-426
pubmed: 29224962
BMC Med Res Methodol. 2008 Nov 27;8:79
pubmed: 19036172
Lancet Infect Dis. 2019 Jun;19(6):e213-e220
pubmed: 30709666
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Hum Vaccin Immunother. 2016;12(2):358-74
pubmed: 26905681
Genes (Basel). 2019 Oct 25;10(11):
pubmed: 31731573
Lancet Infect Dis. 2011 Oct;11(10):760-8
pubmed: 21621466
Clin Infect Dis. 2017 Nov 13;65(11):1780-1789
pubmed: 29020171
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Lancet. 2011 Dec 3;378(9807):1962-73
pubmed: 21492929
PLoS One. 2016 Mar 08;11(3):e0151125
pubmed: 26953887
Clin Infect Dis. 2020 Jun 10;70(12):2484-2492
pubmed: 31402387